アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human ZAP70 (phospho Y292). The exact sequence is proprietary.
This product is a recombinant rabbit monoclonal antibody.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Alternative versions available:
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
Our Abpromise guarantee covers the use of ab76501 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000 - 1/10000. Predicted molecular weight: 70 kDa.|
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
|ICC/IF||1/250 - 1/500.|
Blocking and dilution buffer: 5% NFDM/TBST.
Dot blot analysis of varying amounts of ZAP70 (pY292) phospho peptide (Lane 1) and ZAP70 non-phospho peptide (Lane 2) using ab76501 at a dilution of 1/1000. A peroxidase-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/2500).
Exposure time: 3 minutes.
Immunocytochemistry/Immunofluorescence analysis of untreated and pervanadate treated Jurkat (human acute T cell leukemia) cells labelling ZAP70 (phospho Y292) with ab76501 at a dilution of 1/250. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Treated samples were starved overnight followed by incubation with 1mM pervanadate for 30 minutes. ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. DAPI (blue) was used as the nuclear counterstain. Negative control using secondary antibody only.
Image shows increased cytoplasmic staining after pervanadate treatment.
ab76501 has not yet been referenced specifically in any publications.